论文部分内容阅读
应用单克隆抗体(MTS_1-P_(16(C-20))、PAb-DO-1-P_(53)免疫组化技术对38例高、中、低三种不同分化的前列腺癌MTS_1-P_(16)与突变P_(53)的表达率进行了比较研究。结果显示:在高、中、低三种不同分化的前列腺癌组织切片中MTS_1-P_(16)的阳性表达率为46.2％、21.4％和10％:突变P_(53)的阳性表达率为38.5％、71.4％和72.7％。MTS_1-P_(16)与突变P_(53)总的阳性表达率为23.6％和60.5％。结果提示:MTS_1-P_(16)的表达率随细胞分化恶化而丢失;突变P_(53)随细胞分化恶化表达率升高,MTS_1-P_(16)与P_(53)的丢失、突变与过度表达与肿瘤的发生及恶性生物学行为有关,同时测定MTS_1-P_(16)与突变P_(53)可作为评价前列腺癌预后新的生物学指标。
Using monoclonal antibody (MTS_1-P_(16(C-20)), PAb-DO-1-P_(53) immunohistochemistry technique, three high-, middle-, and low-grade differentiated prostate cancers MTS_1-P_ ( 16) Comparing with the expression rate of mutant P_53, the results showed that the positive expression rate of MTS_1-P_(16) was 46.2% and 21.4 in three different differentiated prostate cancer tissue sections at high, middle and low levels. The positive expression rates of % and 10%: mutation P_(53) were 38.5%, 71.4% and 72.7%, and the total positive expression rates of MTS_1-P_(16) and mutation P_(53) were 23.6% and 60.5%. : The expression rate of MTS_1-P_(16) was lost with the worsening of cell differentiation; the expression of mutant P_(53) increased with the worsening of cell differentiation, and the loss, mutation and overexpression of MTS_1-P_(16) and P_(53) The occurrence of tumors is related to malignant biological behavior. Simultaneous determination of MTS_1-P_(16) and mutation P_(53) can be used as a new biological indicator for evaluating the prognosis of prostate cancer.